Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Mar;58(3):293–299. doi: 10.1136/jnnp.58.3.293

Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Y Ben-Shlomo 1, M G Marmot 1
PMCID: PMC1073364  PMID: 7897409

Abstract

Most previous studies that have examined the survival of patients with parkinsonism have recruited them from specialist centres. No previous study has ever reported cause specific mortality. We report on the mortality of a cohort of 220 parkinsonian patients recruited between 1970 and 1972 from 40 primary health care practices all over England and Wales and matched to 421 controls. At 20 years of follow up, 195 cases (88.6%) and 295 controls (70.1%) were no longer alive (P < 0.001). The median age at death for cases was 77.6 (range 53.8-97.3) and 83.5 (range 55.0-100.1) for controls (P < 0.001). The all cause hazard ratio for cases compared with controls was 2.6 (95% confidence interval (95% CI) 2.2-3.2) controlling for age, sex, and geographical region. There was little difference between men and women. Differences for cause specific mortality also emerged. Both ischemic heart disease (2.3, 95% CI 1.5-3.4) and cerebrovascular disease (3.6, 95% CI 2.2-6.1) showed significantly increased hazard ratios. Possible reasons for these findings are discussed in terms of (a) competing causes of death, (b) a secondary effect of drug treatment, and (c) common aetiological factors for both parkinsonism and cardiovascular disease.

Full text

PDF
293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARBEAU A., JOLY J. G. [Parkinsonism and cancer]. Union Med Can. 1963 Feb;92:169–174. [PubMed] [Google Scholar]
  2. Baron J. A. Cigarette smoking and Parkinson's disease. Neurology. 1986 Nov;36(11):1490–1496. doi: 10.1212/wnl.36.11.1490. [DOI] [PubMed] [Google Scholar]
  3. Ben-Shlomo Y. Smoking and neurogenerative diseases. Lancet. 1993 Nov 13;342(8881):1239–1239. [PubMed] [Google Scholar]
  4. Black D. W., Fisher R. Mortality in DSM-IIIR schizophrenia. Schizophr Res. 1992 Jul;7(2):109–116. doi: 10.1016/0920-9964(92)90040-c. [DOI] [PubMed] [Google Scholar]
  5. Curtis L., Lees A. J., Stern G. M., Marmot M. G. Effect of L-dopa on course of Parkinson's disease. Lancet. 1984 Jul 28;2(8396):211–212. doi: 10.1016/s0140-6736(84)90493-8. [DOI] [PubMed] [Google Scholar]
  6. Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990 May;40(5):763–766. doi: 10.1212/wnl.40.5.763. [DOI] [PubMed] [Google Scholar]
  7. Diamond S. G., Markham C. H., Hoehn M. M., McDowell F. H., Muenter M. D. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology. 1989 Sep;39(9):1187–1190. doi: 10.1212/wnl.39.9.1187. [DOI] [PubMed] [Google Scholar]
  8. Diamond S. G., Markham C. H. Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm. 1976;38(3-4):259–269. doi: 10.1007/BF01249443. [DOI] [PubMed] [Google Scholar]
  9. EADIE M. J., SUTHERLAND J. M. ARTERIOSCLEROSIS IN PARKINSONISM. J Neurol Neurosurg Psychiatry. 1964 Jun;27:237–240. doi: 10.1136/jnnp.27.3.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ebmeier K. P., Calder S. A., Crawford J. R., Stewart L., Besson J. A., Mutch W. J. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study. Scott Med J. 1990 Dec;35(6):173–175. doi: 10.1177/003693309003500605. [DOI] [PubMed] [Google Scholar]
  11. Ebmeier K. P., Calder S. A., Crawford J. R., Stewart L., Besson J. A., Mutch W. J. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand. 1990 Apr;81(4):294–299. doi: 10.1111/j.1600-0404.1990.tb01558.x. [DOI] [PubMed] [Google Scholar]
  12. Férnandez-Calle P., Molina J. A., Jiménez-Jiménez F. J., Vázquez A., Pondal M., García-Ruiz P. J., Urra D. G., Domingo J., Codoceo R. Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease. Neurology. 1992 May;42(5):1064–1066. doi: 10.1212/wnl.42.5.1064. [DOI] [PubMed] [Google Scholar]
  13. Golbe L. I., Farrell T. M., Davis P. H. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord. 1990;5(1):66–70. doi: 10.1002/mds.870050116. [DOI] [PubMed] [Google Scholar]
  14. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  15. Hughes A. J., Ben-Shlomo Y., Daniel S. E., Lees A. J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992 Jun;42(6):1142–1146. doi: 10.1212/wnl.42.6.1142. [DOI] [PubMed] [Google Scholar]
  16. Isles C. G., Hole D. J. Is there a J curve distribution for diastolic blood pressure? Clin Exp Hypertens A. 1992;14(1-2):139–149. doi: 10.3109/10641969209036177. [DOI] [PubMed] [Google Scholar]
  17. Iwasaki S., Hamaguchi K., Iwasaki A., Takakusagi M., Narabayashi Y. Hypotensive effect of long-term levodopa in patients with Parkinson's disease. Eur Neurol. 1990;30(4):194–199. doi: 10.1159/000117344. [DOI] [PubMed] [Google Scholar]
  18. Jenner P., Schapira A. H., Marsden C. D. New insights into the cause of Parkinson's disease. Neurology. 1992 Dec;42(12):2241–2250. doi: 10.1212/wnl.42.12.2241. [DOI] [PubMed] [Google Scholar]
  19. Joseph C., Chassan J. B., Koch M. L. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol. 1978 Feb;3(2):116–118. doi: 10.1002/ana.410030205. [DOI] [PubMed] [Google Scholar]
  20. Kessler I. I. Epidemiologic studies of Parkinson's disease. 3. A community-based survey. Am J Epidemiol. 1972 Oct;96(4):242–254. doi: 10.1093/oxfordjournals.aje.a121455. [DOI] [PubMed] [Google Scholar]
  21. Kircher T., Nelson J., Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med. 1985 Nov 14;313(20):1263–1269. doi: 10.1056/NEJM198511143132005. [DOI] [PubMed] [Google Scholar]
  22. Marttila R. J., Rinne U. K. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg. 1976;79(1):46–56. doi: 10.1016/s0303-8467(76)80005-4. [DOI] [PubMed] [Google Scholar]
  23. Mutch W. J., Dingwall-Fordyce I., Downie A. W., Paterson J. G., Roy S. K. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):534–536. doi: 10.1136/bmj.292.6519.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nelson L. M., Franklin G. M., Hamman R. F., Boteler D. L., Baum H. M., Burks J. S. Referral bias in multiple sclerosis research. J Clin Epidemiol. 1988;41(2):187–192. doi: 10.1016/0895-4356(88)90093-5. [DOI] [PubMed] [Google Scholar]
  25. Newens A. J., Forster D. P., Kay D. W. Death certification after a diagnosis of presenile dementia. J Epidemiol Community Health. 1993 Aug;47(4):293–297. doi: 10.1136/jech.47.4.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Newman S. C., Bland R. C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991 May;36(4):239–245. doi: 10.1177/070674379103600401. [DOI] [PubMed] [Google Scholar]
  27. Phillips A. N., Smith G. D. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol. 1991;44(11):1223–1231. doi: 10.1016/0895-4356(91)90155-3. [DOI] [PubMed] [Google Scholar]
  28. Pollock M., Hornabrook R. W. The prevalence, natural history and dementia of Parkinson's disease. Brain. 1966 Sep;89(3):429–448. doi: 10.1093/brain/89.3.429. [DOI] [PubMed] [Google Scholar]
  29. Przuntek H., Welzel D., Blümner E., Danielczyk W., Letzel H., Kaiser H. J., Kraus P. H., Riederer P., Schwarzmann D., Wolf H. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol. 1992;43(4):357–363. doi: 10.1007/BF02220609. [DOI] [PubMed] [Google Scholar]
  30. Rajput A. H., Offord K. P., Beard C. M., Kurland L. T. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984 Sep;16(3):278–282. doi: 10.1002/ana.410160303. [DOI] [PubMed] [Google Scholar]
  31. Riggs J. E. Smoking and Alzheimer's disease: protective effect or differential survival bias? Lancet. 1993 Sep 25;342(8874):793–794. doi: 10.1016/0140-6736(93)91547-y. [DOI] [PubMed] [Google Scholar]
  32. Rimm E. B., Stampfer M. J., Ascherio A., Giovannucci E., Colditz G. A., Willett W. C. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993 May 20;328(20):1450–1456. doi: 10.1056/NEJM199305203282004. [DOI] [PubMed] [Google Scholar]
  33. Rinne U. K., Sonninen V., Siirtola T., Marttila R. Long-term responses of Parkinson's disease to levodopa therapy. J Neural Transm Suppl. 1980;(16):149–156. doi: 10.1007/978-3-7091-8582-7_16. [DOI] [PubMed] [Google Scholar]
  34. Rose G., Shipley M. Effects of coronary risk reduction on the pattern of mortality. Lancet. 1990 Feb 3;335(8684):275–277. doi: 10.1016/0140-6736(90)90082-g. [DOI] [PubMed] [Google Scholar]
  35. Saito I., Kawabe H., Hasegawa C., Iwaida Y., Yamakawa H., Saruta T., Takeshita E., Nagano S., Sekihara T. Effect of L-dopa in young patients with hypertension. Angiology. 1991 Sep;42(9):691–695. doi: 10.1177/000331979104200902. [DOI] [PubMed] [Google Scholar]
  36. Scigliano G., Musicco M., Soliveri P., Piccolo I., Girotti F., Giovannini P., Caraceni T. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology. 1990 Feb;40(2):265–269. doi: 10.1212/wnl.40.2.265. [DOI] [PubMed] [Google Scholar]
  37. Struck L. K., Rodnitzky R. L., Dobson J. K. Stroke and its modification in Parkinson's disease. Stroke. 1990 Oct;21(10):1395–1399. doi: 10.1161/01.str.21.10.1395. [DOI] [PubMed] [Google Scholar]
  38. Sutcliffe R. L., Prior R., Mawby B., McQuillan W. J. Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability. Acta Neurol Scand. 1985 Oct;72(4):363–379. doi: 10.1111/j.1600-0404.1985.tb00886.x. [DOI] [PubMed] [Google Scholar]
  39. Uitti R. J., Ahlskog J. E., Maraganore D. M., Muenter M. D., Atkinson E. J., Cha R. H., O'Brien P. C. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology. 1993 Oct;43(10):1918–1926. doi: 10.1212/wnl.43.10.1918. [DOI] [PubMed] [Google Scholar]
  40. Zumstein H., Siegfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol. 1976;14(5):321–328. doi: 10.1159/000114756. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES